Novavax Company Profile (NASDAQ:NVAX)

About Novavax (NASDAQ:NVAX)

Novavax logoNovavax, Inc. is a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants. The Company operates through developing recombinant vaccines segment. The Company, through its recombinant nanoparticle vaccine technology, produces vaccine candidates to respond to both known and newly emerging diseases. The Company's product pipeline focuses on a range of infectious diseases with vaccine candidates in clinical development for respiratory syncytial virus (RSV), seasonal influenza, pandemic influenza and the Ebola virus (EBOV). The Company's lead adjuvant for human applications, Matrix-M, is in a Phase I/II clinical trial for pandemic influenza H7N9 vaccine candidate. It is also testing Matrix-M in conjunction with its EBOV vaccine candidate in a Phase I clinical trial. It is developing additional pre-clinical stage programs in a range of infectious diseases, including Middle East respiratory syndrome (MERS).

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology & Medical Research - NEC
  • Sub-Industry: Biotechnology
  • Symbol: NASDAQ:NVAX
  • CUSIP: 67000210
  • Web:
  • Market Cap: $418.24 million
  • Outstanding Shares: 282,595,000
Average Prices:
  • 50 Day Moving Avg: $1.15
  • 200 Day Moving Avg: $1.18
  • 52 Week Range: $0.73 - $8.49
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -2.85
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: $16.82 million
  • Price / Sales: 24.87
  • Book Value: ($0.10) per share
  • Price / Book: -14.80
  • EBIDTA: ($221,620,000.00)
  • Net Margins: -1,466.36%
  • Return on Equity: -787.38%
  • Return on Assets: -56.67%
  • Debt-to-Equity Ratio: -10.89%
  • Current Ratio: 4.57%
  • Quick Ratio: 4.57%
  • Average Volume: 6.38 million shs.
  • Beta: 1.99
  • Short Ratio: 10.78
Frequently Asked Questions for Novavax (NASDAQ:NVAX)

What is Novavax's stock symbol?

Novavax trades on the NASDAQ under the ticker symbol "NVAX."

How were Novavax's earnings last quarter?

Novavax, Inc. (NASDAQ:NVAX) released its quarterly earnings data on Monday, May, 8th. The company reported ($0.16) EPS for the quarter, beating the Thomson Reuters' consensus estimate of ($0.18) by $0.02. The business had revenue of $5.68 million for the quarter, compared to the consensus estimate of $6.17 million. Novavax had a negative net margin of 1,466.36% and a negative return on equity of 787.38%. The company's revenue was up 34.6% compared to the same quarter last year. During the same period in the prior year, the firm earned ($0.29) earnings per share. View Novavax's Earnings History.

Where is Novavax's stock going? Where will Novavax's stock price be in 2017?

9 brokers have issued twelve-month target prices for Novavax's shares. Their forecasts range from $1.00 to $25.00. On average, they anticipate Novavax's stock price to reach $5.71 in the next year. View Analyst Ratings for Novavax.

What are analysts saying about Novavax stock?

Here are some recent quotes from research analysts about Novavax stock:

  • 1. Cantor Fitzgerald analysts commented, "Important RSV vaccine data to be released next Monday. NVAX plans to host a conference call on Monday, July 24, at 4:30pm EDT, on which top-line data from the E-205 Phase 2 clinical trial of the RSV vaccine candidate in older adults will be discussed. The company’s press release notes that an update of the ongoing pivotal Prepare trial of the vaccine candidate in pregnant women will also be provided. Of the two programs, we believe the former is likely to be the greater value creator and, if the data are encouraging, could provide a catalyst for renewed investor interest in the stock." (7/21/2017)
  • 2. According to Zacks Investment Research, "NOVAVAX INC is a specialty biopharmaceutical company engaged in the research, development and commercialization of proprietary products focused on women's health and infectious diseases. Their technology platforms involve the use of proprietary, microscopic, organized, non-phospholipid structures as vehicles for the delivery of a wide variety of drugs and other therapeutic products, including certain hormones, anti-bacterial and anti-viral products and vaccine adjuvants. " (6/10/2017)
  • 3. Chardan Capital analysts commented, "The company is at a pre-commercialization stage, although it does recognize revenue from research and development collaborations. Reported revenue in Q4 was $5.4M, which was inline with consensus." (2/28/2017)

Are investors shorting Novavax?

Novavax saw a drop in short interest in June. As of June 30th, there was short interest totalling 56,851,825 shares, a drop of 11.6% from the June 15th total of 64,277,879 shares. Based on an average trading volume of 6,096,592 shares, the days-to-cover ratio is presently 9.3 days. Currently, 20.4% of the shares of the stock are sold short.

Who are some of Novavax's key competitors?

Who are Novavax's key executives?

Novavax's management team includes the folowing people:

  • James Francis Young Ph.D., Independent Chairman of the Board
  • Stanley C. Erck, President, Chief Executive Officer, Director
  • Barclay A. Phillips, Chief Financial Officer, Senior Vice President, Treasurer
  • Gregory M. Glenn M.D., President, Research and Development
  • John A. Herrmann III, Senior Vice President, General Counsel, Corporate Secretary
  • John J. Trizzino, Senior Vice President - Commercial Operations
  • James F. Cummings, Vice President - Clinical Development and Translational Medicine
  • Rajiv I. Modi Ph.D., Director
  • Gail Koziara Boudreaux, Independent Director
  • Richard H. Douglas Ph.D., Independent Director

Who owns Novavax stock?

Novavax's stock is owned by many different of institutional and retail investors. Top institutional investors include Creative Planning (0.17%). Company insiders that own Novavax stock include Barclay A Phillips, Gail Boudreaux, Gary C Evans, Gregory M Glenn, John A Herrmann III, John Trizzino, Michael A Mcmanus Jr and Stanley C Erck. View Institutional Ownership Trends for Novavax.

Who bought Novavax stock? Who is buying Novavax stock?

Novavax's stock was purchased by a variety of institutional investors in the last quarter, including Creative Planning. Company insiders that have bought Novavax stock in the last two years include Barclay A Phillips, Gail Boudreaux, Gregory M Glenn, John A Herrmann III, John Trizzino, Michael A Mcmanus Jr and Stanley C Erck. View Insider Buying and Selling for Novavax.

How do I buy Novavax stock?

Shares of Novavax can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Novavax's stock price today?

One share of Novavax stock can currently be purchased for approximately $1.48.

MarketBeat Community Rating for Novavax (NASDAQ NVAX)
Community Ranking:  3.1 out of 5 (  )
Outperform Votes:  203 (Vote Outperform)
Underperform Votes:  124 (Vote Underperform)
Total Votes:  327
MarketBeat's community ratings are surveys of what our community members think about Novavax and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Novavax (NASDAQ:NVAX) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 7 Hold Ratings, 2 Buy Ratings
Consensus Rating:Hold (Score: 2.22)
Consensus Price Target: $5.71 (285.73% upside)

Analysts' Ratings History for Novavax (NASDAQ:NVAX)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
7/21/2017Cantor FitzgeraldReiterated RatingHold$2.00LowView Rating Details
3/1/2017Ladenburg Thalmann Financial ServicesReiterated RatingNeutralN/AView Rating Details
2/28/2017Chardan CapitalReiterated RatingHold$1.50N/AView Rating Details
1/18/2017FBR & CoReiterated RatingOutperform$12.00N/AView Rating Details
11/11/2016WedbushReiterated RatingNeutral$2.00 -> $1.50N/AView Rating Details
11/10/2016J P Morgan Chase & CoReiterated RatingHoldN/AView Rating Details
9/16/2016S&P Equity ResearchLower Price Target$1.44 -> $1.17N/AView Rating Details
9/16/2016Citigroup Inc.DowngradeBuy -> Neutral$12.00 -> $1.50N/AView Rating Details
9/16/2016Piper Jaffray CompaniesDowngradeOverweight -> Neutral$14.00 -> $1.00N/AView Rating Details
8/29/2016GuggenheimReiterated RatingBuy$25.00N/AView Rating Details
(Data available from 7/23/2015 forward)


Earnings History for Novavax (NASDAQ:NVAX)
Earnings by Quarter for Novavax (NASDAQ:NVAX)
Earnings History by Quarter for Novavax (NASDAQ NVAX)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/8/2017Q1 2017($0.18)($0.16)$6.17 million$5.68 millionViewListenView Earnings Details
2/27/2017Q416($0.23)($0.21)$5.45 million$5.40 millionViewListenView Earnings Details
11/9/2016Q316($0.26)($0.24)$4.02 million$3.20 millionViewListenView Earnings Details
8/9/2016Q216($0.25)($0.29)$8.03 million$2.50 millionViewListenView Earnings Details
5/4/2016Q1($0.27)($0.29)$10.39 million$4.20 millionViewListenView Earnings Details
2/29/2016Q415($0.14)($0.29)$8.07 million$5.90 millionViewListenView Earnings Details
11/9/2015Q315($0.09)($0.12)$10.59 million$6.50 millionViewN/AView Earnings Details
8/10/2015Q215($0.09)($0.08)$9.90 million$14.00 millionViewListenView Earnings Details
5/7/2015Q115($0.11)($0.10)$9.70 million$9.88 millionViewN/AView Earnings Details
2/26/2015Q4 14($0.08)($0.13)$9.60 million$6.70 millionViewN/AView Earnings Details
11/5/2014Q314($0.07)($0.08)$9.20 million$8.20 millionViewN/AView Earnings Details
8/6/2014Q214($0.07)($0.08)$8.74 million$8.26 millionViewN/AView Earnings Details
5/7/2014Q114($0.07)($0.07)$3.80 million$7.50 millionViewN/AView Earnings Details
3/10/2014Q413($0.08)($0.07)$6.22 million$8.70 millionViewN/AView Earnings Details
11/7/2013Q313($0.06)($0.09)$4.56 million$4.80 millionViewN/AView Earnings Details
8/8/2013Q2 2013($0.06)($0.08)$4.45 million$3.50 millionViewN/AView Earnings Details
5/7/2013Q1 2013($0.06)($0.07)$5.54 million$3.80 millionViewN/AView Earnings Details
3/1/2013Q4 2012($0.04)($0.06)$5.85 million$4.57 millionViewN/AView Earnings Details
11/2/2012Q312($0.05)($0.05)$7.59 million$5.80 millionViewN/AView Earnings Details
8/3/2012($0.07)($0.05)ViewN/AView Earnings Details
5/4/2012($0.04)($0.06)ViewN/AView Earnings Details
3/9/2012($0.04)($0.03)ViewN/AView Earnings Details
11/4/2011($0.06)($0.03)ViewN/AView Earnings Details
8/5/2011($0.08)($0.04)ViewN/AView Earnings Details
5/9/2011($0.07)($0.07)ViewN/AView Earnings Details
3/28/2011($0.09)($0.06)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Novavax (NASDAQ:NVAX)
2017 EPS Consensus Estimate: ($0.66)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20172($0.19)($0.17)($0.18)
Q2 20172($0.16)($0.16)($0.16)
Q3 20172($0.17)($0.16)($0.17)
Q4 20172($0.16)($0.14)($0.15)
(Data provided by Zacks Investment Research)


Dividend History for Novavax (NASDAQ:NVAX)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading and Institutional Ownership History for Novavax (NASDAQ:NVAX)
Insider Ownership Percentage: 4.00%
Institutional Ownership Percentage: 49.98%
Insider Trades by Quarter for Novavax (NASDAQ:NVAX)
Institutional Ownership by Quarter for Novavax (NASDAQ:NVAX)
Insider Trades by Quarter for Novavax (NASDAQ:NVAX)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
5/12/2017Michael A Mcmanus JrDirectorBuy20,000$0.97$19,400.00View SEC Filing  
5/11/2017Barclay A PhillipsCFOBuy25,000$0.84$21,000.00View SEC Filing  
5/11/2017Michael A Mcmanus JrDirectorBuy10,000$0.84$8,400.00View SEC Filing  
5/11/2017Stanley C ErckInsiderBuy50,000$0.84$42,000.00View SEC Filing  
1/31/2017Barclay A. PhillipsCFOBuy1,633$1.12$1,828.96View SEC Filing  
1/31/2017John A. Herrmann IIISVPBuy4,960$1.12$5,555.20View SEC Filing  
12/7/2016Gregory M GlennInsiderBuy1,000$1.45$1,450.00View SEC Filing  
9/22/2016John TrizzinoSVPBuy46,000$2.17$99,820.00View SEC Filing  
9/21/2016Gregory M GlennInsiderBuy1,000$1.65$1,650.00View SEC Filing  
9/21/2016Michael A Mcmanus JrDirectorBuy30,000$1.61$48,300.00View SEC Filing  
9/20/2016Gail BoudreauxDirectorBuy100,000$1.45$145,000.00View SEC Filing  
7/31/2016Barclay A. PhillipsCFOBuy422$4.29$1,810.38View SEC Filing  
6/6/2016Gary C EvansDirectorSell18,998$6.50$123,487.00View SEC Filing  
5/24/2016Gary C EvansDirectorSell50,000$5.41$270,500.00View SEC Filing  
3/31/2016Stanley C ErckCEOSell424,778$5.19$2,204,597.82View SEC Filing  
1/31/2016Barclay A. PhillipsCFOBuy405$4.38$1,773.90View SEC Filing  
1/31/2016Gregory M. GlennSVPBuy2,369$4.38$10,376.22View SEC Filing  
1/31/2016Stanley C. ErckCEOBuy2,072$4.38$9,075.36View SEC Filing  
12/16/2015John A Herrmann IIISVPSell27,945$8.64$241,444.80View SEC Filing  
8/24/2015Gary C EvansDirectorSell20,000$11.24$224,800.00View SEC Filing  
8/20/2015Barclay A. PhillipsCFOSell28,656$13.06$374,247.36View SEC Filing  
8/18/2015Gregory M. GlennSVPSell15,000$13.52$202,800.00View SEC Filing  
8/13/2015Gary C EvansDirectorSell6,002$13.56$81,387.12View SEC Filing  
6/18/2015James F YoungDirectorSell50,000$9.47$473,500.00View SEC Filing  
6/17/2015Rajiv I ModiDirectorSell433,053$9.01$3,901,807.53View SEC Filing  
6/11/2015Rajiv I ModiDirectorSell11,185$9.00$100,665.00View SEC Filing  
6/10/2015Rajiv I ModiDirectorSell551,081$8.97$4,943,196.57View SEC Filing  
6/9/2015Rajiv I ModiDirectorSell47,531$8.93$424,451.83View SEC Filing  
6/8/2015Rajiv I ModiDirectorSell206,175$8.93$1,841,142.75View SEC Filing  
6/4/2015Rajiv I ModiDirectorSell504,681$8.92$4,501,754.52View SEC Filing  
6/1/2015Rajiv I ModiDirectorSell3,500,000$8.74$30,590,000.00View SEC Filing  
1/31/2015Barclay A PhillipsCFOBuy8,388$2.28$19,124.64View SEC Filing  
1/31/2015John TrizzinoSVPBuy6,611$3.63$23,997.93View SEC Filing  
1/31/2015Stanley C ErckCEOBuy6,122$2.28$13,958.16View SEC Filing  
12/16/2014Gary C EvansDirectorSell46,701$5.72$267,129.72View SEC Filing  
12/12/2014Gary C EvansDirectorSell30,000$5.77$173,100.00View SEC Filing  
11/20/2014Rajiv I ModiDirectorSell518,889$5.02$2,604,822.78View SEC Filing  
11/18/2014Rajiv I ModiDirectorSell1,481,111$5.00$7,405,555.00View SEC Filing  
10/3/2014Barclay A PhillipsCFOBuy5,000$4.11$20,550.00View SEC Filing  
10/3/2014Timothy Jon HahnSVPBuy2,500$4.05$10,125.00View SEC Filing  
9/26/2014Gregory M GlennSVPSell16,809$4.16$69,925.44View SEC Filing  
9/25/2014Timothy Jon HahnSVPBuy9,000$4.17$37,530.00View SEC Filing  
7/31/2014Barclay A PhillipsCFOBuy8,788$2.28$20,036.64View SEC Filing  
7/31/2014Russell P WilsonSVPBuy4,989$2.28$11,374.92View SEC Filing  
7/31/2014Stanley C ErckCEOBuy6,788$2.28$15,476.64View SEC Filing  
6/17/2014John TrizzinoSVPBuy5,500$4.51$24,805.00View SEC Filing  
6/16/2014John TrizzinoSVPBuy16,500$4.51$74,415.00View SEC Filing  
3/25/2014Barclay PhillipsCFOBuy5,000$4.25$21,250.00View SEC Filing  
3/25/2014Richard DouglasDirectorBuy50,000$4.33$216,500.00View SEC Filing  
3/25/2014Stanley ErckCEOBuy10,000$4.27$42,700.00View SEC Filing  
3/21/2014Pharmaceuticals Ltd Cadilamajor shareholderSell3,000,000$4.95$14,850,000.00View SEC Filing  
1/31/2014Barclay PhillipsCFOBuy9,868$2.29$22,597.72View SEC Filing  
1/31/2014Stanley ErckCEOBuy11,868$2.29$27,177.72View SEC Filing  
1/31/2014Timothy Jon HahnSVPBuy9,416$2.29$21,562.64View SEC Filing  
6/12/2013Richard DouglasDirectorBuy50,000$1.90$95,000.00View SEC Filing  
6/10/2013Timothy Jon HahnSVPBuy21,000$1.88$39,480.00View SEC Filing  
6/7/2013Gregory M GlennInsiderBuy2,000$1.92$3,840.00View SEC Filing  
6/6/2013James F YoungDirectorBuy100,000$1.91$191,000.00View SEC Filing  
3/11/2013James F YoungDirectorBuy100,000$2.03$203,000.00View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for Novavax (NASDAQ:NVAX)
Latest Headlines for Novavax (NASDAQ:NVAX)
DateHeadline logoShould Investors Brace for Bad News From Novavax's Looming Clinical Update? - July 23 at 6:39 AM logoShould Investors Brace for Bad News From Novavax's Looming Clinical Update? - July 22 at 2:38 PM logoReminder: Novavax to Host an RSV F Vaccine Update Conference Call and Webcast on July 24, 2017 at 4:30 PM - July 22 at 7:04 AM logoNovavax, Inc. (NASDAQ:NVAX) Stock Rating Reaffirmed by Cantor Fitzgerald - July 21 at 7:48 AM logoHere's Why Novavax, Inc. Stock Popped Today - Motley Fool - July 19 at 6:17 AM logoGainers & Losers Of July 18: CAPR, NVAX, TTOO, IMUC, SBPH... - July 19 at 12:31 AM logoNovavax (NVAX) Plans RSV F Vaccine Update Conference Call and Webcast on July 24 - July 19 at 12:31 AM logoToday's Research Reports on Trending Tickers: Puma Biotechnology Inc. and Novavax Inc. - July 19 at 12:31 AM logoHere's Why Novavax, Inc. Stock Popped Today - July 19 at 12:31 AM logoWhy Rite Aid, Novavax, and RH Jumped Today - July 19 at 12:31 AM logoHere's Why Novavax, Inc. Stock Popped Today - July 18 at 1:17 PM logoNovavax to host RSV F vaccine update July 24; shares ahead 8% premarket - July 18 at 7:55 AM logoNovavax (NVAX) Plans RSV F Vaccine Update Conference Call and Webcast on July 24 - - July 18 at 6:49 AM logoNovavax to Host an RSV F Vaccine Update Conference Call and Webcast on July 24, 2017 at 4:30 PM - July 18 at 6:48 AM logoNovavax, Inc. (NASDAQ:NVAX) Short Interest Down 11.6% in June - July 15 at 7:16 AM logoWhy Novavax Stock Surged Higher in June - July 13 at 7:27 AM logoZacks: Brokerages Anticipate Novavax, Inc. (NASDAQ:NVAX) Will Announce Quarterly Sales of $5.90 Million - July 8 at 10:30 AM logoNovavax, Inc. (NVAX) Expected to Post Earnings of -$0.16 Per Share - July 6 at 10:42 AM logoNovavax, Inc. (NASDAQ:NVAX) Given Average Rating of "Hold" by Analysts - July 3 at 6:52 PM logoNovavax, Inc. Forecasted to Post FY2018 Earnings of ($0.48) Per Share (NVAX) - June 26 at 8:16 AM logoNovavax, Inc. (NVAX) Expected to Post Quarterly Sales of $5.90 Million - June 14 at 12:38 PM logo Brokerages Expect Novavax, Inc. (NVAX) to Announce -$0.16 Earnings Per Share - June 12 at 12:14 PM logoShort Interest in Novavax, Inc. (NVAX) Expands By 4.8% - June 11 at 7:22 AM logoNovavax, Inc. (NVAX) Cut to Hold at Zacks Investment Research - June 10 at 2:26 PM logoNovavax, Inc. (NVAX) Upgraded at Zacks Investment Research - June 10 at 7:22 AM logoNovavax (NVAX) Says RSV F Vaccine Phase 2 Clinical Trial Data Published in Vaccine - June 9 at 12:48 AM logoToday's Research Reports on Stocks to Watch: Kite Pharma and Novavax - June 8 at 9:40 AM logoNovavax stock surges 6% after release of full mid-stage vaccine trial results - June 7 at 6:44 PM logoThese 2 Catalysts Are Behind Novavax, Inc.'s 12% Rise in May - June 7 at 6:44 PM logoThese 2 Catalysts Are Behind Novavax, Inc.'s 12% Rise in May - June 7 at 11:42 AM logoNovavax (NVAX) Says RSV F Vaccine Phase 2 Clinical Trial Data Published in Vaccine - - June 7 at 8:22 AM logoNovavax RSV F Vaccine Phase 2 Clinical Trial Data in Women of Child Bearing Age Published in Vaccine - June 7 at 8:22 AM logoNovavax, Inc. (NVAX) Given Consensus Recommendation of "Hold" by Analysts - June 6 at 6:41 PM logoValuEngine Downgrades Novavax, Inc. (NVAX) to Strong Sell - June 3 at 11:58 PM logoNovavax's Pipeline: Plenty Of Ammunition - Seeking Alpha - June 1 at 7:46 PM logoFBR & Co Weighs in on Novavax, Inc.'s Q2 2017 Earnings (NVAX) - May 29 at 7:04 AM logoCan The Uptrend Continue for Novavax (NVAX)? - May 26 at 7:55 PM logoShort Interest in Novavax, Inc. (NVAX) Increases By 3.4% - May 26 at 7:12 AM logoETFs with exposure to Novavax, Inc. : May 22, 2017 - May 22 at 6:09 PM logoNovavax Financial Review, Analysts Target and Outlook - May 19 at 11:41 AM logoToday's Research Reports on Biotech Stocks to Watch: Novavax and Progenics Pharmaceuticals - May 19 at 11:41 AM logo$5.81 Million in Sales Expected for Novavax, Inc. (NVAX) This Quarter - May 17 at 9:10 AM logoNovavax, Inc. breached its 50 day moving average in a Bullish Manner : NVAX-US : May 16, 2017 - May 16 at 10:07 AM logoBiotech Movers: Akebia, Editas, Novavax - May 16 at 10:07 AM logoHere's What's Driving Up Novavax, Inc. Stock Again Today - May 15 at 6:16 PM logoHere's What's Driving Up Novavax, Inc. Stock Again Today - May 15 at 1:25 PM logoHere's What Is Pushing Up Novavax, Inc. Stock Today - Motley Fool - May 13 at 8:21 AM logoNovavax, Inc. (NVAX) Given Consensus Rating of "Hold" by Analysts - May 12 at 7:00 PM logoInsider Buying: Novavax, Inc. (NVAX) Director Acquires 20,000 Shares of Stock - May 12 at 4:46 PM logoFY2017 EPS Estimates for Novavax, Inc. Boosted by Analyst (NVAX) - May 12 at 12:32 PM



Novavax (NVAX) Chart for Sunday, July, 23, 2017

This page was last updated on 7/23/2017 by Staff